Quince Therapeutics, Inc.QNCXNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank50
3Y CAGR-3.9%
5Y CAGR-10.2%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-3.9%/yr
vs +43.9%/yr prior
5Y CAGR
-10.2%/yr
Recent acceleration
Acceleration
-47.9pp
Decelerating
Percentile
P50
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $46.14M | -19.5% |
| 2024 | $57.28M | +65.5% |
| 2023 | $34.62M | -33.4% |
| 2022 | $52.02M | -42.4% |
| 2021 | $90.32M | +14.5% |
| 2020 | $78.89M | +101.4% |
| 2019 | $39.17M | +223.2% |
| 2018 | $12.12M | +16.9% |
| 2017 | $10.37M | - |